Adam Koppel is Director & 10% Owner at Cerevel Therapeutics Holdings, Inc. (CERE). They have made 13 open-market trades across 9 companies since 2013, most recently 2026-04-20.
CIK 0001578965
9 open-market purchases totalling $426.8M since 2013, against 4 sales. Across 9 scored buys the stock is up 5.5% at ninety days, and 4.5 points ahead of the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 56% | 67% | 56% |
| Avg Move | +0.6% | +9.8% | +5.5% |
| Alpha | +0.7% | +8.9% | +4.5% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KLRA | BUY | 2026-04-20 | 2026-04-20 | $16.00 | $25.0M | +0.6% | -19.3% | -28.0% |
| CERE | BUY | 2023-10-16 | 2023-10-18 | $22.81 | $250.0M | -1.8% | +4.1% | +79.9% |
| SWTX | SELL | 2021-03-09 | 2021-03-11 | $71.50 | $103.7M | -9.6% | -8.9% | +13.6% |
| DRNA | SELL | 2020-12-10 | 2020-12-14 | $23.40 | $23.4M | -5.8% | -5.3% | +12.9% |
| CERE | BUY | 2020-11-09 | 2020-11-12 | $10.30 | $6.8M | +9.1% | +36.5% | +23.2% |
| CERE | BUY | 2020-10-27 | 2020-10-29 | $10.00 | $100.0M | +4.3% | +38.4% | +22.7% |
| ARQT | BUY | 2020-02-04 | 2020-02-06 | $17.00 | $5.0M | +7.6% | +14.8% | +2.0% |
| APTX | BUY | 2020-01-14 | 2020-01-16 | $3.00 | $10.0M | -1.0% | -9.0% | -36.4% |
| DRNA | SELL | 2019-12-04 | 2019-12-06 | $24.68 | $37.0M | -1.6% | -18.8% | -25.9% |
| APTX | BUY | 2018-06-25 | 2018-06-26 | $16.00 | $6.4M | +20.3% | +10.5% | +31.9% |
| SLDB | BUY | 2018-01-30 | 2018-02-01 | $16.00 | $4.8M | -5.1% | +14.0% | -43.5% |
| BIIB | SELL | 2016-06-06 | 2016-06-07 | $290.00 | $161K | -6.6% | -3.0% | +21.8% |
| BIIB | SELL · 10b5-1 | 2016-04-06 | 2016-04-07 | $275.00 | $28K | -1.5% | -1.8% | -10.0% |
| PTCT | BUY | 2013-06-25 | 2013-06-28 | $15.00 | $18.8M | -28.3% | -2.3% | -2.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| BIIB | 2,402 | $559K |
| DRNA | 3,333 | $127K |
| BLSA | 487,500 | — |
| Total | $797.0M |
Shares reported on the most recent Form 4, priced at the 2026-04-20 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.